EQT Fund Management S.a r.l. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001834239

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedTechnology Tilt how tags are computed

Q3 2026 · 6 positions · Total reported value $947.44M · Top-10 concentration 100.0% · Updated 2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

Turnover: 16.7% · 1 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, EQT Fund Management S.a r.l. disclosed 6 equity positions with a combined reported value of $947.44M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Technology Tilt.

The largest disclosed positions as of Q3 2026 were WAY ($630.44M), PHVS ($108.63M), OCS ($64.92M). By sector, the heaviest allocations are Technology 66.5%, Health Care 29.0%. Versus the prior quarter, allocation shifted toward Technology (+7.3pp), Other (+4.5pp) and away from Health Care (-11.8pp).

Versus the prior quarter, EQT Fund Management S.a r.l. opened 1 new positions, trimmed 0 and fully exited 0, a turnover rate of 16.7% of positions. The portfolio's overlap with the prior quarter was 83% of names.

The largest new positions opened in Q3 2026 were GRTX ($42.70M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • GRTX ELECTRA THERAPEUTICS INC · $42.70M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest EQT Fund Management S.a r.l. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

EQT Fund Management S.a r.l. files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 5 positions worth $862.62M in total. HoldingsHub carries 4 quarters of its filings (Q3 2025–Q2 2026).

Portfolio Structure

  • 5 positions · $862.62M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: WAY (WAYSTAR HLDG CORP) at 59.2%
  • Average position size: $172.52M

Sector Tilt

  • Information Technology 59.2%
  • Health Care 40.8%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 2 added
  • 3 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased its allocation to WAYSTAR HLDG CORP (Technology) while reducing weights in Health Care names (PHVS, OCS, AGMB, EVMN), suggesting a tilt toward large-cap tech over biotech/healthcare, possibly driven by price appreciation rather than active buying. 2. Key moves: - Added: GRTX (ELECTRA THERAPEUTICS INC), 4.51% new position. - Reduced: No explicit reductions (action=Hold for all others; weight declines attributed to price effects). 3. Portfolio structure: Active (concentrated top-10 holdings), overweight Technology (66.54%) vs. Health Care (28.94%), high risk (single stock WAYSTAR at 66.54%). 4. Per-holding one-liner: - WAYSTAR HLDG CORP (Technology): Cloud-based healthcare software provider. - PHARVARIS N V (Health Care): Biopharma focused on respiratory diseases. - Oculis Holding AG (Health Care): Ophthalmology drug developer. - Agomab Therapeutics NV (Health Care): Autoimmune disease therapeutics. - EVOMMUNE INC (Health Care): Immuno-oncology biotech. - ELECTRA THERAPEUTICS INC (Health Care): Antibody discovery platform (unverified). 5. Style summary: Concentrated tech-biotech fund with a bullish tilt toward WAYSTAR, adding a small biotech position while passively rebalancing via price-driven weight shifts.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-13 03:39

Sector Allocation

Technology 66.5%
Health Care 29.0%
Other 4.5%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 24.88M $630.44M 66.54%
66.54%
Hold
2 3.42M $108.63M 11.46%
11.46%
Hold
3 6.95M $64.92M 6.85%
6.85%
Hold
4 5.14M $57.08M 6.02%
6.02%
Hold
5 5.29M $43.68M 4.61%
4.61%
Hold
6 3.80M $42.70M 4.51%
4.51%
New

FAQ

What did EQT Fund Management S.a r.l. buy in 2026-Q3?

In its 2026-Q3 13F filing, EQT Fund Management S.a r.l. reported 6 equity positions worth $947.44M in aggregate; its largest disclosed positions were WAY ($630.44M), PHVS ($108.63M), OCS ($64.92M).

How large is EQT Fund Management S.a r.l.'s portfolio?

EQT Fund Management S.a r.l. reported $947.44M of long equity holdings across 6 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is EQT Fund Management S.a r.l.'s investment style?

HoldingsHub classifies the portfolio as Small / Focused / Technology Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/eqt-fund-management-s-a-r-l/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →